We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis.
- Authors
Spekhorst, Lotte S.; Bakker, Daphne; Drylewicz, Julia; Rispens, Theo; Loeff, Floris; Boesjes, Celeste M.; Thijs, Judith; Romeijn, Geertruida L. E.; Loman, Laura; Schuttelaar, Marie‐Louise; van Wijk, Femke; de Graaf, Marlies; de Bruin‐Weller, Marjolein S.
- Abstract
Background: At present, no real‐world studies are available on different dupilumab dosing regimens in controlled atopic dermatitis (AD). The aim of this study was to clinically evaluate a patient‐centered dupilumab dosing regimen in patients with controlled AD and to relate this to serum drug levels and serum biomarkers. Methods: Ninety adult AD patients from the prospective BioDay registry were included based on their dupilumab administration interval according to a predefined patient‐centered dosing regimen. Group A (n = 30) did not fulfill the criteria for interval prolongation and continued using the standard dupilumab dosage (300 mg/2 weeks), group B (n = 30) prolonged dupilumab interval with 50% (300 mg/4 weeks), and group C (n = 30) prolonged dupilumab interval with 66%–75% (300 mg/6–8 weeks). AD severity score, patient‐reported outcomes, serum dupilumab levels, and serum biomarkers were analyzed over time. Results: Disease severity scores did not significantly change over time during the tapering period in any of the groups. In groups B and C, the Numeric Rating Scale (NRS)‐pruritus temporarily significantly increased after interval prolongation but remained low (median NRS‐pruritus≤4). Median dupilumab levels remained stable in group A (standard dosage), but significantly decreased in groups B and C (24.1 mg/L (IQR = 17.1–45.6); 12.5 mg/L (IQR = 1.7–22.3)) compared with the levels during the standard dosage (88.2 mg/L [IQR = 67.1–123.0, p <.001]). Disease severity biomarker levels (CCL17/CCL18) remained low in all study groups during the whole observation period. Conclusions: This study showed that dose reduction was successful in a subgroup of patients with controlled AD by using a patient‐centered dosing regimen. These patients showed stable low disease activity and low severity biomarkers over time.
- Subjects
DUPILUMAB; ATOPIC dermatitis; PATIENT reported outcome measures
- Publication
Allergy, 2022, Vol 77, Issue 11, p3398
- ISSN
0105-4538
- Publication type
Article
- DOI
10.1111/all.15439